Journal: Drugs

Article Title: Antibacterials with Novel Chemical Scaffolds in Clinical Development

doi: 10.1007/s40265-024-02137-x

Figure Lengend Snippet: Global pipeline of small-molecule antibiotics with reported clinical trials

Article Snippet: Nacubactam (OP0595, FPI-1459, RG6080, RO7079901) + meropenem , DBO BLI + carbapenem , Meiji Seika, Roche , Cell wall (PBP) , NCT02134834 (I), NCT02975388 (I), NCT03182504 (I), NCT02972255 (I), NCT03174795 (I) , [ ] .

Techniques: Infection, Disruption, DNA Synthesis, Binding Assay, Membrane, Polymer

Journal: The Journal of Antibiotics

Article Title: Antibiotics in the clinical pipeline as of December 2022

doi: 10.1038/s41429-023-00629-8

Figure Lengend Snippet: β-Lactam/β-lactamase inhibitor (BL/BLI) combinations in clinical trials or submitted for regulatory approval (structures in Figs. 11 – 13 )

Article Snippet: Nacubactam ( 65 ) (OP0595, FPI-1459, RG6080, RO7079901; IV) is a DBO-type BLI [ – ], which was developed by Meiji Seika Pharma (Tokyo, Japan).

Techniques: Clinical Proteomics, Full Display Name, CtB Assay

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: Characteristics of the strains used

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: Estimation of fT >MICi . (a) Simulated free plasma nacubactam PK profile; (b) calculated aztreonam MIC i transition after administration of nacubactam based on the dose–response curve; (c) free plasma aztreonam PK profile (solid orange line) and aztreonam MIC i transition (blue dashed line) were superimposed. The % fT >MICi is the percentage of time that the free plasma aztreonam concentration exceeded the MIC i . This figure appears in colour in the online version of JAC and in black and white in the print version of JAC .

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: Concentration Assay

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: MIC curve between the aztreonam MIC and the nacubactam concentration ( n = 3). (a) NDM-1-positive K. pneumoniae ATCC BAA-2473; (b) IMP-6-positive K. pneumoniae MSC 21664; (c) OXA-48-positive K. pneumoniae MSC 21444.

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: Concentration Assay

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: PK profiles of nacubactam (a) and aztreonam (b) in neutropenic mice (mean ± SD, n = 3).

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: In vivo dose-fractionation study of aztreonam/nacubactam against a neutropenic murine model of thigh infection with NDM-1-positive K. pneumoniae ATCC BAA-2473 (mean ± SD, n = 3). Aztreonam was administered every 2 h, and nacubactam was administered with variable frequency: every 2 h, every 4 h and every 8 h.

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: In Vivo, Fractionation, Infection

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: In vivo dose-ranging study of aztreonam/nacubactam against a neutropenic murine model of thigh infection with IMP-6-positive K. pneumoniae MSC 21664 (a) and OXA-48-positive K. pneumoniae MSC 21444 (b) (mean ± SD, n = 3). Both nacubactam and aztreonam were administered every 2 h.

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: In Vivo, Infection

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: PK/PD analysis and target fT >MICi values of aztreonam with/without nacubactam.

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques:

Journal: Journal of Antimicrobial Chemotherapy

Article Title: Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

doi: 10.1093/jac/dkad033

Figure Lengend Snippet: PK/PD analysis based on fT > C T with optimal C T values of nacubactam (a), f AUC 24 of nacubactam (b), and fC max of nacubactam (c).

Article Snippet: According to CLSI guidelines, , chequerboard MICs of aztreonam/nacubactam were determined by broth microdilution using CAMHB (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) ( n = 3).

Techniques: